MET and non-small cell lung carcinoma: Promising results were also obtained in a phase I trial that combined the MET small-molecule inhibitor savolitinib together with osimertinib and recruited patients with EGFR+ NSCLC harboring MET amplification post treatment with an EGFR inhibitor [140].